BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...said Dominic Smethurst joined as CMO, a new position. Previously, he held the same role at Tusk Therapeutics...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...Viracta Therapeutics Inc. as CMO, effective May 1. Smethurst was the group medical director at Tusk Therapeutics Ltd....
BioCentury | Feb 21, 2020
Emerging Company Profile

Montis: Exploring an untouched macrophage subset in immuno-oncology

...see "Volastra Raises $12M Seed to Shut Down Metastasis" ). Dochez was previously CEO of Tusk Therapeutics...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...The December deal came just over a year after Roche took out another IL-2 company, Tusk Therapeutics Ltd....
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...Cancer Miss” ; “Lilly Shells Out for Armo” ). It also dwarfs the price of Tusk Therapeutics Ltd....
BioCentury | Oct 19, 2018
Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

...NSCLC) and urothelial cancer. In another deal announced Sept. 28, Roche acquired cancer immunotherapy company Tusk Therapeutics Ltd....
BioCentury | Oct 15, 2018
Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

...NSCLC) and urothelial cancer. In another deal announced Sept. 28, Roche acquired cancer immunotherapy company Tusk Therapeutics Ltd....
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Intelligence Buyer Seller Date U/F cash ($M) Milestones ($M) Disclosed value ($M) Roche (SIX:ROG; OTCQX:RHHBY) Tusk Therapeutics Ltd....
BioCentury | Oct 5, 2018
Company News

Roche gains CD25 program via Tusk takeout

...Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up...
...Black Belt's initial chairman, told BioCentury that the spinout will largely maintain Tusk's management team. Tusk Therapeutics Ltd....
...Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech Inc. Roche Tusk Therapeutics Ltd. CD38 Interleukin-2...
BioCentury | Sep 28, 2018
Company News

Roche gains CD25 program via Tusk takeout

...Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up...
...Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech Inc. Roche Tusk Therapeutics Ltd. CD38 Interleukin-2...
Items per page:
1 - 10 of 14
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...said Dominic Smethurst joined as CMO, a new position. Previously, he held the same role at Tusk Therapeutics...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...Viracta Therapeutics Inc. as CMO, effective May 1. Smethurst was the group medical director at Tusk Therapeutics Ltd....
BioCentury | Feb 21, 2020
Emerging Company Profile

Montis: Exploring an untouched macrophage subset in immuno-oncology

...see "Volastra Raises $12M Seed to Shut Down Metastasis" ). Dochez was previously CEO of Tusk Therapeutics...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...The December deal came just over a year after Roche took out another IL-2 company, Tusk Therapeutics Ltd....
BioCentury | Dec 9, 2019
Company News

Sanofi broadens oncology capabilities, adds IL-2 program via $2.5B Synthorx takeout

...Cancer Miss” ; “Lilly Shells Out for Armo” ). It also dwarfs the price of Tusk Therapeutics Ltd....
BioCentury | Oct 19, 2018
Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

...NSCLC) and urothelial cancer. In another deal announced Sept. 28, Roche acquired cancer immunotherapy company Tusk Therapeutics Ltd....
BioCentury | Oct 15, 2018
Company News

SQZ, Roche expand deal to jointly develop cancer cell therapies

...NSCLC) and urothelial cancer. In another deal announced Sept. 28, Roche acquired cancer immunotherapy company Tusk Therapeutics Ltd....
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...Intelligence Buyer Seller Date U/F cash ($M) Milestones ($M) Disclosed value ($M) Roche (SIX:ROG; OTCQX:RHHBY) Tusk Therapeutics Ltd....
BioCentury | Oct 5, 2018
Company News

Roche gains CD25 program via Tusk takeout

...Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up...
...Black Belt's initial chairman, told BioCentury that the spinout will largely maintain Tusk's management team. Tusk Therapeutics Ltd....
...Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech Inc. Roche Tusk Therapeutics Ltd. CD38 Interleukin-2...
BioCentury | Sep 28, 2018
Company News

Roche gains CD25 program via Tusk takeout

...Roche (SIX:ROG; OTCQX:RHHBY) acquired cancer immunotherapy company Tusk Therapeutics Ltd. (Stevenage, U.K.) for €70 million ($82.2 million) up...
...Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Droia Oncology Ventures Genentech Inc. Roche Tusk Therapeutics Ltd. CD38 Interleukin-2...
Items per page:
1 - 10 of 14